GNTA
Genenta Science S.p.A.
NASDAQ · Healthcare · Biotechnology · IT
$0.96
+1.43%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +22.1%
- EBIT
- +27.6%
- EPS
- +25.5%
- Free cash flow
- -85.4%
- Operating cash flow
- -85.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +36.7%
- EBIT
- +37.8%
- Net income
- +32.6%
- EPS
- +32.7%
- Free cash flow
- -10.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025